368 related articles for article (PubMed ID: 27160424)
21. In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets.
Evans IA; Sun X; Liang B; Vegter AR; Guo L; Lynch TJ; Zhang Y; Zhang Y; Yi Y; Yang Y; Feng Z; Park SY; Shonka A; McCumber H; Qi L; Wu P; Liu G; Lacina A; Wang K; Gibson-Corley KN; Meyerholz DK; Limoli DH; Rosen BH; Yan Z; Bartels DJ; Engelhardt JF
JCI Insight; 2024 Apr; 9(8):. PubMed ID: 38646935
[TBL] [Abstract][Full Text] [Related]
22. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
van de Peppel IP; Doktorova M; Berkers G; de Jonge HR; Houwen RHJ; Verkade HJ; Jonker JW; Bodewes FAJA
J Cyst Fibros; 2019 Mar; 18(2):286-293. PubMed ID: 30279125
[TBL] [Abstract][Full Text] [Related]
23. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
[TBL] [Abstract][Full Text] [Related]
24. Effect of VX-770 (ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells.
Vachel L; Norez C; Becq F; Vandebrouck C
J Cyst Fibros; 2013 Dec; 12(6):584-91. PubMed ID: 23757361
[TBL] [Abstract][Full Text] [Related]
25. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
26. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
27. Curcumin and genistein additively potentiate G551D-CFTR.
Yu YC; Miki H; Nakamura Y; Hanyuda A; Matsuzaki Y; Abe Y; Yasui M; Tanaka K; Hwang TC; Bompadre SG; Sohma Y
J Cyst Fibros; 2011 Jul; 10(4):243-52. PubMed ID: 21441077
[TBL] [Abstract][Full Text] [Related]
28. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
[TBL] [Abstract][Full Text] [Related]
29. Mutation-specific downregulation of CFTR2 variants by gating potentiators.
Avramescu RG; Kai Y; Xu H; Bidaud-Meynard A; Schnúr A; Frenkiel S; Matouk E; Veit G; Lukacs GL
Hum Mol Genet; 2017 Dec; 26(24):4873-4885. PubMed ID: 29040544
[TBL] [Abstract][Full Text] [Related]
30. A common mechanism for CFTR potentiators.
Yeh HI; Sohma Y; Conrath K; Hwang TC
J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713
[TBL] [Abstract][Full Text] [Related]
31. Corrector combination therapies for F508del-CFTR.
Hanrahan JW; Matthes E; Carlile G; Thomas DY
Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
[TBL] [Abstract][Full Text] [Related]
32. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
Liu X; Dawson DC
Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
[TBL] [Abstract][Full Text] [Related]
33. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
[TBL] [Abstract][Full Text] [Related]
34. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
35. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770).
Delaunay JL; Bruneau A; Hoffmann B; Durand-Schneider AM; Barbu V; Jacquemin E; Maurice M; Housset C; Callebaut I; Aït-Slimane T
Hepatology; 2017 Feb; 65(2):560-570. PubMed ID: 28012258
[TBL] [Abstract][Full Text] [Related]
36. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
37. Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.
Veit G; Vaccarin C; Lukacs GL
J Cyst Fibros; 2021 Sep; 20(5):895-898. PubMed ID: 33775603
[TBL] [Abstract][Full Text] [Related]
38. Ion Channel Modulators in Cystic Fibrosis.
Gentzsch M; Mall MA
Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
[TBL] [Abstract][Full Text] [Related]
39. Cystic fibrosis: a model system for precision medicine.
Martiniano SL; Sagel SD; Zemanick ET
Curr Opin Pediatr; 2016 Jun; 28(3):312-7. PubMed ID: 27031658
[TBL] [Abstract][Full Text] [Related]
40. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
